Amit C. Nathwani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amit C. Nathwani has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alice Guérin
Hémostase Inflammation Thrombose, HITh U1176, Université Paris-Saclay, Institut National de la Santé et de la Recherche Medicale, Le Kremlin-Bicêtre, France
1 shared publication- Caterina Casari
Université Paris-Saclay, INSERM, Hémostase inflammation thrombose HITH U1176, Le Kremlin-Bicêtre, France
1 shared publication Charlotte Vayssiere
Haematology Department, Cancer Institute, University College London, London, United Kingdom
1 shared publicationDoyoung Lee
Haematology Department, Cancer Institute, University College London, London, United Kingdom
1 shared publication- Edward G. D. Tuddenham
UCL, Rye, United Kingdom
1 shared publication - Emanuela Valeria Volpi
University of Westminster, School of Life Sciences, London, United Kingdom
1 shared publication
Latest Publications
- 25 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (26) , 3175-3187
Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.
- 25 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (26) , 3175-3187
Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.
- Open Access
- 5 July 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (2) , E131-E134
Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia
- 5 July 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (2) , E131-E134
Open AccessExpression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia